| Literature DB >> 27008969 |
Eleonora Leucci1,2, Roberto Vendramin1,2, Marco Spinazzi2, Patrick Laurette3, Mark Fiers2, Jasper Wouters4, Enrico Radaelli5, Sven Eyckerman6,7, Carina Leonelli8,9, Katrien Vanderheyden8,9, Aljosja Rogiers1,2, Els Hermans10, Pieter Baatsen2, Stein Aerts11, Frederic Amant10, Stefan Van Aelst12,13, Joost van den Oord4, Bart de Strooper2, Irwin Davidson3, Denis L J Lafontaine14, Kris Gevaert6,7, Jo Vandesompele8,9, Pieter Mestdagh8,9, Jean-Christophe Marine1,2.
Abstract
Focal amplifications of chromosome 3p13-3p14 occur in about 10% of melanomas and are associated with a poor prognosis. The melanoma-specific oncogene MITF resides at the epicentre of this amplicon. However, whether other loci present in this amplicon also contribute to melanomagenesis is unknown. Here we show that the recently annotated long non-coding RNA (lncRNA) gene SAMMSON is consistently co-gained with MITF. In addition, SAMMSON is a target of the lineage-specific transcription factor SOX10 and its expression is detectable in more than 90% of human melanomas. Whereas exogenous SAMMSON increases the clonogenic potential in trans, SAMMSON knockdown drastically decreases the viability of melanoma cells irrespective of their transcriptional cell state and BRAF, NRAS or TP53 mutational status. Moreover, SAMMSON targeting sensitizes melanoma to MAPK-targeting therapeutics both in vitro and in patient-derived xenograft models. Mechanistically, SAMMSON interacts with p32, a master regulator of mitochondrial homeostasis and metabolism, to increase its mitochondrial targeting and pro-oncogenic function. Our results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27008969 DOI: 10.1038/nature17161
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962